Consensus Myriad Genetics, Inc.

Stocks

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 23:00:00 17/09/2026 +03			5-day change	1st Jan Change
4.140 ^USD	+7.25%		+23.21%	-32.68%

09-16	Myriad Genetics, Inc. Announces Management Changes	CI
09-09	UBS Adjusts Price Target on Myriad Genetics to $3.60 From $6, Keeps Neutral Rating	MT

Evolution of the Average Target: Myriad Genetics, Inc.

Evolution of the Target Price: Myriad Genetics, Inc.

Changes in Analyst Recommendations: Myriad Genetics, Inc.

36e9dded3f2b998de084debd085.OvFcfrn0mlA2HasnhVMpkLrteEm1Oovm4qSzwbnXmMU.dJkSMIiG0jYOcuZ03QVa6cykTBzeVsacsp3iuNXh_PcX3DgP0pPcIn9smw~b2fb8c4bcfbe933a856e1ddd9582b6b0

Analysts' recommendations: Myriad Genetics, Inc.

09-09	UBS Adjusts Price Target on Myriad Genetics to $3.60 From $6, Keeps Neutral Rating	MT
09-01	Myriad Genetics Shares Fall After Piper Sandler Downgrade	MT
09-01	Piper Sandler Downgrades Myriad Genetics to Underweight From Overweight	MT
02-24	UBS Adjusts Price Target on Myriad Genetics to $6 From $8, Maintains Neutral Rating	MT
11-04	UBS Adjusts Myriad Genetics Price Target to $8 From $6, Maintains Neutral Rating	MT
07/08/25	UBS Adjusts Price Target on Myriad Genetics to $6 From $7, Maintains Neutral Rating	MT
06/08/25	Top Midday Gainers	MT
21/05/25	Myriad Genetics Shares Fall After Downgrade From Scotiabank	MT
21/05/25	Scotiabank Downgrades Myriad Genetics to Sector Perform From Sector Outperform, Adjusts Price Target to $6 From $20	MT
19/05/25	Morgan Stanley Cuts Price Target on Myriad Genetics to $7 From $16, Maintains Equalweight Rating	MT
08/05/25	Wolfe Research Downgrades Myriad Genetics to Peer Perform From Outperform	MT
07/05/25	UBS Adjusts Price Target on Myriad Genetics to $7 From $16, Maintains Neutral Rating	MT
07/05/25	Wells Fargo Downgrades Myriad Genetics to Equalweight From Overweight, Adjusts Price Target to $6 From $22	MT
09/04/25	Guggenheim Downgrades Myriad Genetics to Neutral From Buy	MT
12/03/25	Myriad Genetics Shares Rise After Upgrade From Piper Sandler	MT
12/03/25	Piper Sandler Upgrades Myriad Genetics to Overweight From Neutral, Adjusts Price Target to $12.50 From $11.50	MT
25/02/25	UBS Adjusts Price Target on Myriad Genetics to $16 From $18, Maintains Neutral Rating	MT
09/12/24	Leerink Partners Downgrades Myriad Genetics to Market Perform From Outperform, Cuts Price Target to $21 From $30	MT
18/11/24	Morgan Stanley Cuts Price Target on Myriad Genetics to $21 From $32, Keeps Equalweight Rating	MT
19/09/24	Morgan Stanley Initiates Myriad Genetics at Equalweight With $32 Price Target	MT
19/09/24	Morgan Stanley Initiates Myriad Genetics at Equalweight	MT
28/08/24	Wells Fargo Initiates Myriad Genetics at Overweight With $35 Price Target	MT
27/06/24	Scotiabank Initiates Myriad Genetics at Sector Outperform	MT
13/05/24	Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating	MT
29/01/24	Goldman Sachs Adjusts Myriad Genetics' Price Target to $31 From $28, Maintains Buy Rating	MT

More recommendations

Diagnostic & Testing Substances

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Objective/dr gap
MYRIAD GENETICS, INC.	-	-12.78%
GUARDANT HEALTH, INC.		+11.95%
BIOMÉRIEUX		+9.79%
10X GENOMICS, INC.		-28.27%
CARIS LIFE SCIENCES, INC.		-2.38%
LANTHEUS HOLDINGS, INC.		+7.16%
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.		+34.91%
DIASORIN S.P.A.		-3.28%
AUTOBIO DIAGNOSTICS CO., LTD.		+19.67%
Average		+4.09%
Weighted average by Cap.		+5.28%